Immune Checkpoint Inhibitor-Induced Bullous Pemphigoid: Successful Treatment with Dupilumab while Maintaining Immunotherapy.

IF 0.7 Q4 ONCOLOGY

Case Reports in Oncology Pub Date : 2025-07-25 eCollection Date: 2025-01-01 DOI:10.1159/000547431

Cristina-Maria Florea, Laurent Parmentier, Mohamed Abdou, Grégoire Berthod

{"title":"Immune Checkpoint Inhibitor-Induced Bullous Pemphigoid: Successful Treatment with Dupilumab while Maintaining Immunotherapy.","authors":"Cristina-Maria Florea, Laurent Parmentier, Mohamed Abdou, Grégoire Berthod","doi":"10.1159/000547431","DOIUrl":null,"url":null,"abstract":"Introduction: Immune checkpoint inhibitors (ICIs) represent a new class of antitumor agents in oncology. Their use has been associated with a specific safety profile, known as immune-related adverse events (irAEs), with dermatological toxicities being the most frequently encountered.Case report: We report the case of a bullous pemphigoid (BP) in a metastatic melanoma patient, treated with ipilimumab and nivolumab. This immune-mediated toxicity was controlled by using dupilumab as a steroid-sparing therapy, allowing the reintroduction of immunotherapy without relapse.Conclusion: This case illustrates the complexity of managing some dermatological irAEs and the need for better treatment strategies. Dupilumab is a promising agent for cutaneous irAEs, including ICI-BP. To our knowledge, our case is the first one in which a rechallenge with an ICI was attempted after a dupilumab treatment for an ICI-BP.","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"1171-1177"},"PeriodicalIF":0.7000,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503597/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000547431","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Immune checkpoint inhibitors (ICIs) represent a new class of antitumor agents in oncology. Their use has been associated with a specific safety profile, known as immune-related adverse events (irAEs), with dermatological toxicities being the most frequently encountered.

Case report: We report the case of a bullous pemphigoid (BP) in a metastatic melanoma patient, treated with ipilimumab and nivolumab. This immune-mediated toxicity was controlled by using dupilumab as a steroid-sparing therapy, allowing the reintroduction of immunotherapy without relapse.

Conclusion: This case illustrates the complexity of managing some dermatological irAEs and the need for better treatment strategies. Dupilumab is a promising agent for cutaneous irAEs, including ICI-BP. To our knowledge, our case is the first one in which a rechallenge with an ICI was attempted after a dupilumab treatment for an ICI-BP.

查看原文本刊更多论文

免疫检查点抑制剂诱导的大疱性类天疱疮：在维持免疫治疗的同时使用杜匹单抗成功治疗。

免疫检查点抑制剂（ICIs）是肿瘤领域一类新的抗肿瘤药物。它们的使用与特定的安全性相关，即免疫相关不良事件（irAEs），其中皮肤毒性是最常见的。病例报告：我们报告了转移性黑色素瘤患者的大疱性类天疱疮（BP），用伊匹单抗和纳武单抗治疗。这种免疫介导的毒性通过使用dupilumab作为类固醇保留治疗来控制，允许重新引入免疫治疗而不会复发。结论：本病例说明了处理一些皮肤病irAEs的复杂性和更好的治疗策略的必要性。Dupilumab是一种很有前景的治疗皮肤irAEs的药物，包括ICI-BP。据我们所知，我们的病例是第一例在使用杜匹单抗治疗ICI- bp后再次尝试ICI的病例。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊